News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Basilea Pharmaceutica (BSLN.SW)'s Oncology Drug Candidate BAL101553 Demonstrates Broad Antitumor Activity In Treatment-Resistant Breast Cancer Models As Presented At American Association for Cancer Research


4/7/2014 8:43:06 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

BASEL, Switzerland, April 7, 2014 (GLOBE NEWSWIRE) -- Basilea Pharmaceutica Ltd. (SIX: BSLN) reported today that new data demonstrating the broad activity of Basilea's novel oncology drug candidate BAL101553 in pre-clinical models of human breast cancer, including models resistant to standard agents used for the treatment of breast cancer, were presented at the American Association of Cancer Research (AACR) Annual Meeting in San Diego, California, USA.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES